Jeena Sikho Lifecare Ltd

Meeting Details

• Date and time: 31 August 2026, 3:30 PM–5:00 PM.
• Type and mode: Physical group meeting.
• Event: GIA Healthcare Day.
• Location: Jio World Convention Centre, BKC.
• Purpose: investor interaction with analysts.
• Company participants: Managing Director and senior management.

Q1 FY27 highlights and mix

• Total revenue from operations for Q1 FY27: ₹224.4 crore, up 29% YoY.
• Private-pay IPD revenue ₹84.8 crore, up 26% YoY; admissions 11,500, +33%.
• OPD - Medicine (at-centre) revenue ₹78.9 crore, up 18% YoY; 1.51 lakh footfalls, +22%.
• E-commerce - Medicine (COD) revenue ₹40.5 crore, 1.9x growth; 2.82 lakh orders, +3.9x.
• Day-care - Panchakarma revenue ₹10.0 crore, +46%; 19,419 sessions, +31%.
• IPD - Government Panel revenue ₹5.2 crore, -67% YoY; 975 patients, -52%.
• Consultation (OPD & tele) revenue ₹4.5 crore, +10%; 69,119 consults, +65%.
• Diagnostics revenue ₹1.3 crore (new).
• Total IPD volume (blended) grew 16.9%; IPD revenue up 8.8%.
• MD commentary highlights scale-up and private-pay mix focus for sustainable growth.

Case study publications

• Case studies published in Academia Journal of Medicine and Prakriti - The International Multidisciplinary Research Journal.
• MD Manish Grover among authors; highlights Ayurvedic research commitment.
• Six case studies listed with topics including Vandhyatva, CKD, Vrikk Rog, AKD, Arsha, Mutravaha Srotas.
• Links to all case studies provided; available on the company's website.
• Publication demonstrates ongoing commitment to evidence-based clinical practice.

Case studies published

• Case Study: Ayurvedic approach to Sheeta Pitta with urticaria published in Ayushdhara.
• Case Study: Holistic management of Avatu Granthi Rog published in Ayushdhara.
• Case Study: Role of Ahar, Vihar and Aushadhi in Madhumeh (T2DM) clinical observation published.
• Case Study: Efficacy of Ayurvedic intervention in hypothyroidism in women published in IRJAY.
• Case Study: Ayurvedic management of chronic liver disease with progressed chronic liver failure published.
• Case Study: An Ayurvedic approach to Vrikka Rog in pediatric CKD published.
• Case Study: Ayurvedic management of Chronic Kidney Disease (Vrikka Vikara) published.

Case studies published

• Ayurvedic approach to Sheeta Pitta with urticaria published in Ayushdhara journal.
• Holistic management of Avatu Granthi Rog published in Ayushdhara.
• Role of Ahar, Vihar and Aushadhi in Madhumeh (T2DM) clinical observation published in Ayushdhara.
• Hypothyroidism in women: Ayurvedic intervention efficacy, IRJAY case study.
• Chronic liver disease with progressed chronic liver failure: IRJAY case study.
• Vrikka Rog in pediatric CKD: Ayurvedic approach, IRJAY.
• Chronic Kidney Disease management (Vrikka Vikara): Ayurvedic case study, IRJAY.

Meeting Details

• Date and time: August 10, 2026; time not disclosed.
• Type and mode: earnings conference call; virtual.
• Organiser: Go India Advisors.
• Event: Jeena Sikho Lifecare Q1 FY27 earnings conference call.
• Key company participants: Managing Director; Whole-Time Director; Chief Financial Officer.
• Purpose: discuss Q1 FY27 unaudited results and business update.
• Transcript: available on company website.

Participants

• Key company participants: Managing Director; Whole-Time Director; Chief Financial Officer.

Purpose

• Purpose: earnings discussion and business update for Q1 FY27.

Availability

• Transcript of Earnings Conference Call available on company website.

Capacity Addition

• Proposed Ayurvedic, Naturopathy and Panchkarma hospital at Bareilly to add 40+ beds.
• Estimated investment of ₹85 Lakh funded through internal funds.
• Commencement of operations expected November 2026 with ~14,000 sq ft area.

Meeting Details

• Date: 10 August 2026; earnings conference call held today.
• Organizer: Jeena Sikho Lifecare Limited.
• Event type: Earnings Conference Call; format: audio recording.
• Scope: Discuss unaudited Q1 FY2026-27 results.
• Availability: Recording released on the company website.

Participants

• Key company participants: Managing Director (company leadership).

Purpose

• Purpose: Review unaudited results for Q1 FY2026-27.

Additional Notes

• Recording: Audio file available on company website.
• Transcript/presentation status not specified.

Business Overview

• Core business: integrated Ayurveda healthcare services and products with an asset-light cross-sell model.
• 2,400 beds operational; 62 hospitals and 57 clinics across 23 states; 100+ cities.
• IPO raised ₹55.5 Cr to fund expansion across verticals.
• Migrated to NSE/BSE mainboard in Aug 2025; NABH accreditation program ongoing.
• 3Y top-line CAGR 58% and ROCE 46% reflect scale-driven profitability.

Key Operational Highlights

• Q1FY27 revenue ₹22.44 Cr; YoY +29%, QoQ +4%.
• EBITDA ₹9.21 Cr; EBITDA margin 41%; PAT ₹6.57 Cr; PAT margin 28%.
• Panchkarma revenue +13% YoY; IPD volumes +33% YoY; Day-care volumes +31% YoY.
• Beds operational ~2,400; 62 hospitals; 57 clinics; 23 states.
• Health camps: 72-hour events monthly; ~30% IPD conversion.
• Ultra-luxury wellness resort signed in Manali; 108 rooms, 22 villas planned.
• Social media funnel: 16M followers; 10M+ Acharya Manish Ji channels.
• Franchise network: 31 franchisees; exclusive product sales at clinics.
• NABH accreditations: 51 hospitals + 2 in pipeline; 57 clinics.

Financial Performance

• FY22-FY26 revenue from operations rose from ₹14.65 Cr to ₹80.14 Cr.
• Gross profit margin remained around 89–90% across the period.
• EBITDA rose to ₹34.96 Cr; EBITDA margin 44% in FY26.
• PAT expanded to ₹22.22 Cr; PAT margin ~27% in FY26.
• Total equity grew from ₹3.66 Cr to ₹46.74 Cr; total assets ₹67.31 Cr in FY26.
• CFO ₹26.20 Cr in FY26; cash end-year ₹15.16 Cr.
• Borrowings remained low; FY26 borrowings ₹0.16 Cr.

Capital Structure & Liquidity

• IPO raised ₹55.5 Cr; expansion funding for both verticals.
• Capital-light model with outsourced manufacturing; capex per bed ₹3–4 L.
• Migrated to NSE/BSE mainboard in Aug 2025; consistent dividend payout FY23–FY25.
• Empanelments with CGHS, CAPF, ECHS reduce government/payor risk.
• Franchise network and low debt support flexible-funded growth.

Strategic Priorities & Outlook

• Capex per bed of ₹3–4 L under a franchise-driven, asset-light model.
• Cross-sell flywheel: services and medicines reinforce each other; scale through network.
• Expand government/private payor pipelines via empanelment and NABH governance.
• Ultra-luxury wellness venture in Manali complements core Ayurveda services.
• Beds in pipeline ~450; facilities in pipeline; NABH accreditations in progress.

Risks & Mitigation

• Risks: execution of rapid expansion; regulatory changes; macro demand shifts.
• Mitigations: asset-light, franchise model; diversified payor mix; NABH accreditation; government panels.

Governance & Leadership

• Managing Director: Manish Grover; Independent Directors include Karanvir Bindra, Ankush Kaushal, Priyanka Bansal.
• Executive Director: Dr. Ish Sharma; Chief Financial Officer: Nanak Chand Kaushal.
• Audit committee chaired by an Independent Director; internal auditor: Forvis Mazars.
• Migrated to NSE & BSE mainboard in August 2025; dividend payout track record highlighted.